NCT02196285View on ClinicalTrials.gov

Study to Evaluate Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

March 31, 2016

Conditions
RubellaMeasles
Interventions
BIOLOGICAL

Double viral (MR) vaccine

Measles and Rubella vaccine, as single arm

Trial Locations (1)

21040900

Unidade de Ensaios Clínicos para Imunobiológicos, Rio de Janeiro

All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

lead

The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)

OTHER

NCT02196285 - Study to Evaluate Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella | Biotech Hunter | Biotech Hunter